Monday, February 27, 2012

Biofuels

Biofuels


Breathing New Fire

Self sufficiency in energy requirement is critical to the success of any growing economy. With increasing energy consumption, dependence on fossil fuels will necessarily have to be reduced. Being the fifth largest energy consumer, India imported nearly 70% of its crude oil requirement (90 million tonnes) during 2003-04. Estimates indicate that this figure would rise to 95% by 2030

India has rich biomass resources which can be converted into renewable energy. The Planning Commission, Govt. of India, has launched an ambitious National Mission on Biodiesel to be implemented by a number of government agencies and coordinated by the Ministry of Rural Development. The Mission focuses on the cultivation of the physic nut, Jatropha curcas, a shrubby plant of the castor family. The seed contains 30-40% oil and can be mixed with diesel after trans-esterification. Initially Jatropha cultivation will be demonstrated on 0.4 m ha of wasteland area across the country. The entire cost economics is dependant on the productivity, quality and performance of the raw material. The Government is also discussing a National Biofuel Policy.

DBT has been entrusted through a micro-mission with the task of developing technologies that convert fiber, starch and sugar from woody plants and agricultural wastes into useful biofuel products. The thrust is on developing ethanol using lignocellulosic waste as raw material, identifying recombinant microbial stains for enhanced ethanol recovery, producing high quality raw material for biodiesel production and developing the enzymatic trans-esterfication process for more efficient conversion of oil to biodiesel. For the first time, a systematic scientific survey, characterization and collection of superior accessions of J.curcas from across the country has been taken up. More than 1500 accessions have been collected and characterized. Nurseries have been established at 12 locations for providing quality planting material to the National Mission. Nearly 0.8 million quality plantlets have been planted over an area of 300ha. A special focus is being given to crop improvement and on genes involved in oil biosynthesis. Other 'petro-crops' being investigated include Karanja (Pongamia pinnata), toothbrush tree (Salvadora persica) and Mahua (Madhuca indica) 
With continued policy support and vigorous technology, biofuels could very soon be breathing new fire.

Indian Biotech Industry


Biotech Industry

Indian Biotech Industry: Regional spread
The Indian biotechnology industry is well spread across the length and breadth of the country. Several states such as Andhra Pradesh, Himachal Pradesh, Kerala, Tamil Nadu, Uttaranchal, Uttar Pradesh, and Rajasthan among others have adopted biotech policies and established biotech parks to promote the industry.
Bioclusters
There are over 300 companies that are into the biotech business across the country and another 140 companies that supply technology products to these biotech companies. 

Regional distribution of Biotech Revenue 


 The Southern biocluster is housed mostly in and around Bangalore, Hyderabad and Chennai. The heterogenous nature of the Southern cluster, which has companies ranging from the bioagri to bioinformatics to bioindustrial, has made it an attractive destination for companies to set shop here. The Western cluster is centered around Aurangabad, Ahmedabad, Mumbai and Pune, while companies in the North are primarily located in Delhi-Gurgoan-Noida region
Biotech Parks in India
Lucknow - Health Care, Agriculture, Environment, Industrial Applications, Energy
Andhra Pradesh - Development and scale-up of bioprocesses and technologies
Karnataka - Drugs and Pharma
Punjab - Agribusiness and Certification of Export Goods
Kerala - Traditional Medicines
Himachal Pradesh - Medicinal and Aromatic Plants, Horticulture

 
Revenue Share. 

The Biocluster in the western region is the largest in terms of the revenue generated in financial year 2006 with companies like Serum Institute of India, Venkateshwara Hatcheries and Mahyco-Monsanto leading the way. In fact the Western region is the topper for the fourth year in a row with companies from the region grossing $718 million (Rs. 3234.42 crores) which is half of the national biotech share.

 The southern region continues to be second accounting for 36 percent of the industry revenues; they generated $526 million (Rs. 2367 crores) in FY 06. The prominent companies in this region include Biocon and Rasi Seeds, among others. Companies in the North generated a total revenue of $200 million (Rs. 919.46 crores) and contributed to 14 percent of industry revenues. Panacea Biotec, Eli Lilly and Ranbaxy are some of the major players from the North region.
Special Economic Zones in India
These are engines for economic growth supported by quality infrastructure and an attractive fiscal package with minimum possible regulations. They are expected to trigger a large flow of foreign and domestic investment for building infrastructure and increasing productive capacity thereby leading to generation of additional economic activity and creation of employment opportunities. The incentives and facilities offered to the units in SEZs include:-
Duty free import/domestic procurement of goods for development, operation and maintenance of SEZ units
00% Income Tax exemption on export income for SEZ units under Section 10AA of the Income Tax Act for first 5 years, 50% for next 5 years thereafter and 50% of the ploughed back export profit for next 5 years
Exemption from minimum alternate tax under section 115JB of the Income Tax Act
External commercial borrowing by SEZ units up to US $ 500 million in a year without any maturity restriction through recognized banking channels
Exemption from Central Sales Tax and Service Tax
Single window clearance for Central and State level approvals
Biotech Companies in Biotech Parks allowed 5 year time-frame to meet export obligation norms under the SEZ scheme
India's Intellectual Property Regime Promotes Innovation

Fully TRIPS compliant patent regime provides for product patent protection in all fields of technology
Patenting of new microbes and parts thereof (e.g. novel genes, constructs, vectors etc.) is possible
Procedures simplified to make the system efficient and user-friendly
IP Offices in Chennai, Delhi, Kolkata and Mumbai fully modernized and operational; website of IP offices (www.ipindia.nic.in) launched; online search facilities available through connectivity to international databases
IP administration continuously upgraded vis-à-vis WIPO, EPO, JPO, Korean Patent Office, etc.
Intellectual Property Appellate Board set up in Chennai to ensure speedy disposal of appeals against decisions of Registrar of Trade Marks
New regime encourages investment in R&D from local sources as well as from abroad through joint ventures

Government to set up Biotech Industry R&D Assistance Council
Global experience indicates that innovation in biotechnology occurs in small and medium size enterprises (SMEs) with large industries then taking up manufacturing and marketing activities. However, for India to fulfill its potential and emerge as a strong global player in biotech sector, government's role as champion and catalyst is critical in ushering in an ecosystem that encourages innovation, competitiveness, investment and enterprise development. Public-private partnership is critical to the success of innovation. A seamless interface between academia and industry is essential.

       To stimulate and enhance innovation capabilities of the industry sector and to promote and sustain academia-industry interaction, the Government of India has envisaged the creation of Biotechnology Industry Research & Development Assistance Council (BIRAC). The council is expected to assist industry through a range of services. These are intended to 
  •  access key resources and new technologies
  • offer testing and validation facilities
  • offer timely financial assistance
  • facilitate and promote industrial research through technology transfer and intellectual property management, technology acquisition and technology forecasting
  • In addition, a special cell would be designed to addresses the needs of training and capacity building of SMEs.

Health Biotech Sector


Health Care
Health Biotech Sector - A Defining Moment

Health Biotech Sector - A Defining Moment
The first ever, independent survey of 21 homegrown health biotech firms in India (Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS and Singer PA. 2007. India's health biotech sector at a crossroads. Nature Biotechnology 25 (4): 403-417, April 2007) has revealed that they are not only headed for future growth but also, in some cases, for developing innovative products for world markets. The interview based study found that while policies and support of the government and the expertise and efficiencies of the private sector have each contributed to the development of this sector, it is the creativity and astute management of the firms themselves that has been a crucial element of success.
Lessons learnt
The study provides the following valuable lessons for all developing countries wishing to strengthen their health innovation systems and for individual companies planning to develop or enhance their biotech capacity.
  • Many local firms started small with one or a few familiar products and/or services to generate early revenues, and leveraged early success for later growth
  • Firms have been resourceful in exploring various financial opportunities from both domestic and international sources, without having to surrender much equity
  • Successful firms have proactively established and maintained collaborations and partnerships with both public and private organizations in India and abroad
  • Firms are aiming to become more competitive by patenting their products and technologies globally. At the national level, they have been able to capitalize on the domestic policy of emphasizing process patenting over product patenting to build strong capabilities on generics manufacturing
  • Successful Indian firms have been able to establish and maintain favourable reputations internationally

Barriers to success
However, the survey also pointed out several obstacles that are hindering the development of the health biotech sector:

  • Delays in commercialization caused by multiple regulatory agencies
  • Shortage of advanced training programmes and scarcity of qualified personnel

  • Overall lack of public-private collaionboration
  • Few Indian academics show entrepreneurial ambition in biotech
  • Dearth of financial resources and burdening bureaucracy
  • Lack of national prioritization diverts focus from domestic health needs
  • High cost associated with domestic distribution

Recommendations for development
On the basis of the study, the authors made six recommendations to
encourage continued growth of the sector:
  • Harmonize pharmaceutical regulatory system into one regulatory agency and ensure adequate training for regulatory personnel
  • Increase training programmes in advance biotech through a single agency for science mentoring and guidance
  • Ensure translation of initiatives in the draft Biotech Strategy into policies that increase effective public-private collaboration and encourage academic scientists to pursue entrepreneurial ventures to commercial research
  • Create a favourable and enabling financial environment for enterprise creation and private sector development, including early stage research and product development
  • Identify national priorities for public health and use a targeted funding approach to ensure development of products and services that address local health needs
  • Improve public health infrastructure and/or give incentives to private firms to develop innovative distribution strategies

The findings of this survey will be of interest to biotech firms across the globe seeking partnerships with Indian firms, venture capitalists seeking investment opportunities, foundations interested in global health solutions and developing world governments seeking ideas about successful innovation strategies.

SPECIAL SUPPLEMENT

BOSTONMay 6-9, 2007
BIOPHARMA SECTOR IN THE COUNTRY


India: A New Hub for Clinical Research
  • Large, diverse and therapy-naïve population with varying gene pool
  • Low trial cost per unit patient
  • Suitable legislation in place
  • Clinical research extended to chronic diseases (e.g cardio, nephro, neuro, joints, reproduction etc.)
  • World Class Clinical Research Training and Translational Centres
  • Large number of CROs for initiating collaborative multinational trials
  • Clinical trial units coming up in medical colleges and pharma units